FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070357349> ?p ?o ?g. }

• W2070357349 endingPage "288" @default.
• W2070357349 startingPage "280" @default.
• W2070357349 abstract "The basal (constitutive) activity of G protein-coupled receptors allows for the measurement of inverse agonist activity. Some competitive antagonists turn into inverse agonists under conditions where receptors are constitutively active. In contrast, neutral antagonists have no inverse agonist activity, and they block both agonist and inverse agonist activity. The mu-opioid receptor (MOR) demonstrates detectable constitutive activity only after a state of dependence is produced by chronic treatment with a MOR agonist. We therefore sought to identify novel MOR inverse agonists and novel neutral MOR antagonists in both untreated and agonist-treated MOR cells. CHO cells expressing the cloned human mu receptor (hMOR-CHO cells) were incubated for 20 h with medium (control) or 10 microM (2S,4aR,6aR,7R,9S,10aS,10bR)-9-(benzoyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2H-naphtho-[2,1-c]pyran-7-carboxylic acid methyl ester (herkinorin, HERK). HERK treatment generates a high degree of basal signaling and enhances the ability to detect inverse agonists. [(35)S]-GTP-gamma-S assays were conducted using established methods. We screened 21 MOR antagonists using membranes prepared from HERK-treated hMOR-CHO cells. All antagonists, including CTAP and 6beta-naltrexol, were inverse agonists. However, LTC-274 ((-)-3-cyclopropylmethyl-2,3,4,4alpha,5,6,7,7alpha-octahydro-1H-benzofuro[3,2-e]isoquinolin-9-ol)) showed the lowest efficacy as an inverse agonist, and, at concentrations less than 5 nM, had minimal effects on basal [(35)S]-GTP-gamma-S binding. Other efforts in this study identified KC-2-009 ((+)-3-((1R,5S)-2-((Z)-3-phenylallyl)-2-azabicyclo[3.3.1]nonan-5-yl)phenol hydrochloride) as an inverse agonist at untreated MOR cells. In HERK-treated cells, KC-2-009 had the highest efficacy as an inverse agonist. In summary, we identified a novel and selective MOR inverse agonist (KC-2-009) and a novel MOR antagonist (LTC-274) that shows the least inverse agonist activity among 21 MOR antagonists. LTC-274 is a promising lead compound for developing a true MOR neutral antagonist." @default.
• W2070357349 created "2016-06-24" @default.
• W2070357349 creator A5007922126 @default.
• W2070357349 creator A5014962738 @default.
• W2070357349 creator A5015614509 @default.
• W2070357349 creator A5018269231 @default.
• W2070357349 creator A5018562571 @default.
• W2070357349 creator A5021281916 @default.
• W2070357349 creator A5025530874 @default.
• W2070357349 creator A5035496277 @default.
• W2070357349 creator A5072565784 @default.
• W2070357349 creator A5074242003 @default.
• W2070357349 creator A5075961914 @default.
• W2070357349 creator A5088107347 @default.
• W2070357349 creator A5088476466 @default.
• W2070357349 date "2010-04-01" @default.
• W2070357349 modified "2023-10-17" @default.
• W2070357349 title "Identification of a novel “almost neutral” μ-opioid receptor antagonist in CHO cells expressing the cloned human μ-opioid receptor" @default.
• W2070357349 cites W1722020637 @default.
• W2070357349 cites W1964191104 @default.
• W2070357349 cites W1977913176 @default.
• W2070357349 cites W1989208044 @default.
• W2070357349 cites W2001271898 @default.
• W2070357349 cites W2005643237 @default.
• W2070357349 cites W2009635624 @default.
• W2070357349 cites W2019515560 @default.
• W2070357349 cites W2026168925 @default.
• W2070357349 cites W2032255930 @default.
• W2070357349 cites W2042097750 @default.
• W2070357349 cites W2045514043 @default.
• W2070357349 cites W2046787882 @default.
• W2070357349 cites W2117762969 @default.
• W2070357349 cites W2120122043 @default.
• W2070357349 cites W2131302772 @default.
• W2070357349 cites W2148300669 @default.
• W2070357349 cites W2952774795 @default.
• W2070357349 doi "https://doi.org/10.1002/syn.20723" @default.
• W2070357349 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2821452" @default.
• W2070357349 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19953652" @default.
• W2070357349 hasPublicationYear "2010" @default.
• W2070357349 type Work @default.
• W2070357349 sameAs 2070357349 @default.
• W2070357349 citedByCount "25" @default.
• W2070357349 countsByYear W20703573492012 @default.
• W2070357349 countsByYear W20703573492013 @default.
• W2070357349 countsByYear W20703573492014 @default.
• W2070357349 countsByYear W20703573492015 @default.
• W2070357349 countsByYear W20703573492017 @default.
• W2070357349 countsByYear W20703573492018 @default.
• W2070357349 countsByYear W20703573492020 @default.
• W2070357349 countsByYear W20703573492022 @default.
• W2070357349 countsByYear W20703573492023 @default.
• W2070357349 crossrefType "journal-article" @default.
• W2070357349 hasAuthorship W2070357349A5007922126 @default.
• W2070357349 hasAuthorship W2070357349A5014962738 @default.
• W2070357349 hasAuthorship W2070357349A5015614509 @default.
• W2070357349 hasAuthorship W2070357349A5018269231 @default.
• W2070357349 hasAuthorship W2070357349A5018562571 @default.
• W2070357349 hasAuthorship W2070357349A5021281916 @default.
• W2070357349 hasAuthorship W2070357349A5025530874 @default.
• W2070357349 hasAuthorship W2070357349A5035496277 @default.
• W2070357349 hasAuthorship W2070357349A5072565784 @default.
• W2070357349 hasAuthorship W2070357349A5074242003 @default.
• W2070357349 hasAuthorship W2070357349A5075961914 @default.
• W2070357349 hasAuthorship W2070357349A5088107347 @default.
• W2070357349 hasAuthorship W2070357349A5088476466 @default.
• W2070357349 hasBestOaLocation W20703573492 @default.
• W2070357349 hasConcept C126322002 @default.
• W2070357349 hasConcept C134018914 @default.
• W2070357349 hasConcept C14397066 @default.
• W2070357349 hasConcept C153911025 @default.
• W2070357349 hasConcept C170493617 @default.
• W2070357349 hasConcept C175656101 @default.
• W2070357349 hasConcept C185592680 @default.
• W2070357349 hasConcept C2776885963 @default.
• W2070357349 hasConcept C2778938600 @default.
• W2070357349 hasConcept C2779886867 @default.
• W2070357349 hasConcept C55493867 @default.
• W2070357349 hasConcept C58732023 @default.
• W2070357349 hasConcept C71240020 @default.
• W2070357349 hasConcept C71924100 @default.
• W2070357349 hasConcept C86803240 @default.
• W2070357349 hasConcept C89951826 @default.
• W2070357349 hasConcept C98274493 @default.
• W2070357349 hasConceptScore W2070357349C126322002 @default.
• W2070357349 hasConceptScore W2070357349C134018914 @default.
• W2070357349 hasConceptScore W2070357349C14397066 @default.
• W2070357349 hasConceptScore W2070357349C153911025 @default.
• W2070357349 hasConceptScore W2070357349C170493617 @default.
• W2070357349 hasConceptScore W2070357349C175656101 @default.
• W2070357349 hasConceptScore W2070357349C185592680 @default.
• W2070357349 hasConceptScore W2070357349C2776885963 @default.
• W2070357349 hasConceptScore W2070357349C2778938600 @default.
• W2070357349 hasConceptScore W2070357349C2779886867 @default.
• W2070357349 hasConceptScore W2070357349C55493867 @default.
• W2070357349 hasConceptScore W2070357349C58732023 @default.
• W2070357349 hasConceptScore W2070357349C71240020 @default.
• W2070357349 hasConceptScore W2070357349C71924100 @default.

• next